Universal Beteiligungs und Servicegesellschaft mbH Acquires New Position in United Therapeutics Co. (NASDAQ:UTHR)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 46,777 shares of the biotechnology company's stock, valued at approximately $16,505,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.10% of United Therapeutics at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of UTHR. Janney Montgomery Scott LLC grew its stake in United Therapeutics by 9.1% in the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock valued at $3,326,000 after purchasing an additional 789 shares during the period. Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics during the 4th quarter worth $225,000. Blue Trust Inc. grew its stake in shares of United Therapeutics by 24.2% during the 4th quarter. Blue Trust Inc. now owns 1,745 shares of the biotechnology company's stock worth $625,000 after acquiring an additional 340 shares during the period. Milestone Asset Management LLC grew its stake in shares of United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock worth $1,014,000 after acquiring an additional 1,037 shares during the period. Finally, Capital Investment Advisory Services LLC grew its stake in shares of United Therapeutics by 12.9% during the 4th quarter. Capital Investment Advisory Services LLC now owns 1,242 shares of the biotechnology company's stock worth $438,000 after acquiring an additional 142 shares during the period. Institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on UTHR shares. Cantor Fitzgerald started coverage on United Therapeutics in a research note on Monday. They set an "overweight" rating and a $405.00 price target for the company. Morgan Stanley increased their price target on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Bank of America raised United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a report on Monday, April 21st. Finally, HC Wainwright reissued a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a report on Monday, May 5th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $393.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $1.28 on Tuesday, hitting $324.20. The company's stock had a trading volume of 441,670 shares, compared to its average volume of 440,468. The company has a 50-day simple moving average of $300.11 and a 200 day simple moving average of $334.17. United Therapeutics Co. has a 1 year low of $266.98 and a 1 year high of $417.82. The company has a market capitalization of $14.62 billion, a PE ratio of 14.24, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same quarter last year, the firm posted $6.17 EPS. The company's revenue was up 17.2% compared to the same quarter last year. On average, equities research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company's stock, valued at approximately $2,703,424. This trade represents a 22.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Raymond Dwek sold 3,000 shares of the firm's stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $285.16, for a total value of $855,480.00. Following the transaction, the director now directly owns 1,750 shares in the company, valued at approximately $499,030. This represents a 63.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 56,500 shares of company stock valued at $16,923,950 in the last 90 days. Corporate insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.